Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000419 · ClinicalTrials.gov registry record · Phase 3
Safety of Estrogens in Lupus: Hormone Replacement Therapy
A Phase 3 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00000419 is a Phase 3 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 350 participants.
The verdict
NCT00000419, a Phase 3 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
Interventions
- DRUG Premarin and Provera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 1996-04 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000419
The ClinicalTrials.gov registry entry for NCT00000419 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Premarin and Provera is the first listed.
NCT00000419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000419 about?
NCT00000419 is a clinical study titled "Safety of Estrogens in Lupus: Hormone Replacement Therapy". Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on t...
What is the current status of trial NCT00000419?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 1996-04. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00000419?
The interventions under investigation include: Premarin and Provera (DRUG).
Who is sponsoring clinical trial NCT00000419?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.